- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gamco Investors Buys $2.24M Stake in Ralliant Corporation
Institutional investor takes position in medical technology company focused on regenerative medicine
Published on Mar. 11, 2026
Got story updates? Submit your updates here. ›
Gamco Investors INC. ET AL, a major institutional investor, has purchased a new stake of 51,297 shares in Ralliant Corporation (NYSE:RAL), a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The stake is valued at approximately $2.24 million.
Why it matters
This investment by a prominent institutional investor like Gamco Investors suggests confidence in Ralliant's technology and growth potential in the regenerative medicine market. Ralliant's proprietary device platforms and processing kits aim to streamline the workflow for clinicians providing same-day, autologous cell therapy treatments.
The details
According to a recent 13F filing, Gamco Investors purchased the 51,297 shares of Ralliant in the 3rd quarter. Several other institutional investors and hedge funds have also bought and sold Ralliant shares in recent quarters, including Envestnet Asset Management, Bank of New York Mellon, and Resona Asset Management.
- Gamco Investors purchased the Ralliant shares in the 3rd quarter of the year.
The players
Gamco Investors INC. ET AL
A major institutional investor that purchased a new stake in Ralliant Corporation.
Ralliant Corporation
A medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine.
The takeaway
Gamco Investors' investment in Ralliant Corporation signals confidence in the company's regenerative medicine technology and growth potential. As the field of cell therapy continues to evolve, Ralliant's proprietary platforms aimed at streamlining clinical workflows could position it for success.
